TCGA-AC-A2FK-01A-12R-A180-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 88
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.410
- UV_RESPONSE_DN+0.390
- HEDGEHOG_SIGNALING+0.280
- APICAL_JUNCTION+0.260
- KRAS_SIGNALING_UP+0.240
- TGF_BETA_SIGNALING+0.240
- TNFA_SIGNALING_VIA_NFKB+0.230
- ANDROGEN_RESPONSE+0.210
- NOTCH_SIGNALING+0.180
- APICAL_SURFACE+0.130
Top 10 suppressed
- E2F_TARGETS-0.650
- MYC_TARGETS_V1-0.550
- G2M_CHECKPOINT-0.540
- OXIDATIVE_PHOSPHORYLATION-0.520
- MYC_TARGETS_V2-0.500
- MTORC1_SIGNALING-0.460
- DNA_REPAIR-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- UV_RESPONSE_UP-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A1G6-01A-11R-A13Q-07 | — | A | 0.927 |
| 2 | BSR_05_0025_A4_S57 | — | A | 0.896 |
| 3 | TCGA-BH-A0E9-01B-11R-A115-07 | — | A | 0.884 |
| 4 | TCGA-97-8172-01A-11R-2287-07 | — | cohortA1 | 0.881 |
| 5 | TCGA-A7-A4SC-01A-12R-A266-07 | — | A | 0.880 |
| 6 | TCGA-50-8457-01A-11R-2326-07 | — | cohortA1 | 0.868 |
| 7 | SRR8613708 | — | A | 0.865 |
| 8 | TCGA-B6-A0IH-01A-11R-A115-07 | — | A | 0.861 |
| 9 | TCGA-55-8206-01A-11R-2241-07 | — | cohortA1 | 0.860 |
| 10 | TCGA-D8-A4Z1-01A-21R-A266-07 | — | A | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.010 | Idelalisib | — uncovered |